LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC

Stopped The decision was made to close the study to enrollment due to poor overall accrual and the inability to meet the 31% overall enrollment goal.

Conditions

• Hepatocellular Carcinoma

Interventions

• DRUG: Atezolizumab and bevacizumab
• RADIATION: transarterial chemoembolization (TACE) or transarterial radioembolization (TARE

Sponsor

University of Texas Southwestern Medical Center

Collaborators

• [object Object]